Treatment of Herpes Simplex Virus (HSV) Scalp Infection

First-Line Treatment Options

The Centers for Disease Control and Prevention recommends oral antiviral therapy with acyclovir 400 mg three times daily for 7-10 days as the first-line treatment for HSV scalp infections 1
Acyclovir 200 mg orally five times daily for 7-10 days is also recommended for initial HSV scalp infection 1
Famciclovir 250 mg orally three times daily for 7-10 days is a recommended treatment option for HSV scalp infections 1
Valacyclovir 1 g orally twice daily for 7-10 days is a recommended treatment option for HSV scalp infections 1

For recurrent HSV scalp infections, the Centers for Disease Control and Prevention recommends shorter treatment courses, including acyclovir 400 mg orally three times daily for 5 days 2
Acyclovir 200 mg orally five times daily for 5 days is also recommended for recurrent HSV scalp infections 2
Famciclovir 125 mg orally twice daily for 5 days is a recommended treatment option for recurrent HSV scalp infections 2
Valacyclovir 500 mg orally twice daily for 5 days is a recommended treatment option for recurrent HSV scalp infections 2

The Centers for Disease Control and Prevention recommends daily suppressive therapy for patients with frequent recurrences (≥6 episodes per year), including acyclovir 400 mg orally twice daily 4
Famciclovir 250 mg orally twice daily is a recommended treatment option for suppressive therapy 4
Valacyclovir 250 mg orally twice daily is a recommended treatment option for suppressive therapy 4
Suppressive therapy reduces recurrence frequency by ≥75% in patients with frequent episodes 3

For severe HSV scalp infections requiring hospitalization, the Centers for Disease Control and Prevention recommends acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 6

For immunocompromised patients, higher doses of antivirals are recommended, including acyclovir 400 mg orally 3-5 times daily until clinical resolution 6
Famciclovir 500 mg twice daily has been effective in reducing recurrences and subclinical shedding in HIV-infected patients 6

Topical therapy with acyclovir is substantially less effective than systemic treatment and is not recommended 1
Treatment should be initiated as early as possible for optimal effectiveness, ideally within 72 hours of symptom onset 5
No laboratory monitoring is needed for patients receiving antiviral therapy unless they have significant renal impairment 3

Delaying treatment beyond 72 hours significantly reduces effectiveness 5
Using topical therapy alone has poor efficacy compared to systemic treatment 1
Failing to consider suppressive therapy in patients with frequent recurrences 3
Discontinuing immunosuppressive therapy prematurely in patients with inflammatory bowel disease who develop HSV infections 7